Provided by Tiger Fintech (Singapore) Pte. Ltd.

RxSIGHT, INC.

7.97
+0.03000.38%
Post-market: 7.990.0200+0.25%19:44 EDT
Volume:776.47K
Turnover:6.17M
Market Cap:323.88M
PE:-11.95
High:8.09
Open:8.00
Low:7.71
Close:7.94
Loading ...

BUZZ-Jefferies starts coverage on Rxsight with 'buy' on growth potential

Reuters
·
24 Mar

U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy

Reuters
·
24 Mar

RxSight Is Maintained at Buy by B of A Securities

Dow Jones
·
21 Mar

RxSight (RXST) Gets a Hold from Stifel Nicolaus

TIPRANKS
·
19 Mar

Promising Growth and Competitive Edge: A Buy Rating for RxSight

TIPRANKS
·
04 Mar

Top Premarket Gainers

MT Newswires Live
·
04 Mar

RxSight, Inc. Reports Strong Revenue Growth Amid Challenges

TIPRANKS
·
28 Feb

RxSight Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St.
·
27 Feb

Stock Track | RxSIGHT, INC. (RXST) Plunges 6.06% as Analysts Lower Price Targets

Stock Track
·
26 Feb

Stifel Nicolaus Sticks to Their Hold Rating for RxSight (RXST)

TIPRANKS
·
26 Feb

RxSight price target lowered to $44 from $58 at BTIG

TIPRANKS
·
26 Feb

RxSight Price Target Maintained With a $43.00/Share by Needham

Dow Jones
·
26 Feb

RxSight Inc (RXST) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

GuruFocus.com
·
26 Feb

RxSight, Inc. Reports Strong 2024 Financial Growth

TIPRANKS
·
26 Feb

BTIG Keeps Their Buy Rating on RxSight (RXST)

TIPRANKS
·
26 Feb

RxSight, Inc. (RXST) Misses Q4 Earnings Estimates

Zacks
·
26 Feb

Rxsight Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
26 Feb

RxSight Q4 2024 Adj. EPS $0.03 Up From $(0.13) YoY, Sales $40.214M Miss $40.318M Estimate

Benzinga
·
26 Feb

BRIEF-Rxsight Q4 Operating Expenses USD 37.4 Million

Reuters
·
26 Feb

Stifel Nicolaus Remains a Hold on RxSight (RXST)

TIPRANKS
·
18 Feb